Immune checkpoints such as the CD80/86-CTLA and the PD-L1-PD-1 axes have recently gained much attention, since their therapeutic targeting elicits immune responses, particularly in melanoma that is characterized by a high mutation rate and occurrence of tumor (neo-) antigens. The gene discussed is CD274; the disease is neoplasm.